Sunday, June 26, 2022

Investing in Caribou Biosciences Inc. (CRBU): What You Must Know

Caribou Biosciences Inc.’s recent filing unveils that its VP of Finance and Controller Fischesser Ryan acquired Company’s shares for reported $29553.0 on Jan 11. In the deal valued at $4.00 per share,7,387 shares were bought. As a result of this transaction, Fischesser Ryan now holds 109,082 shares worth roughly $ 0.6 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Then, Fischesser Ryan bought 1,136 shares, generating $3,056 in total proceeds. Upon buying the shares at $2.69, the VP of Finance and Controller now owns 101,695 shares.

Before that, MCCLUNG BARBARA G bought 6,127 shares. Caribou Biosciences Inc. shares valued at $16,482 were divested by the Chief Legal Officer at a price of $2.69 per share. As a result of the transaction, MCCLUNG BARBARA G now holds 348,971 shares, worth roughly $1.93 million.

Meanwhile, RBC Capital Mkts initiated its Caribou Biosciences Inc. [CRBU] rating to an Outperform in a research note published on Tuesday, February 18, 2022; the price target was $22. PT values the company’s stock at a premium of 74.91 to its Tuesday closing price. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in early December with a ‘”an Outperform”‘ rating. H.C. Wainwright began covering CRBU with a “Buy” recommendation on November 30, 2021. Citigroup revised its rating on November 15, 2021. It rated CRBU as “a Buy” which previously was an “a Neutral”.

Price Performance Review of CRBU

On Tuesday, Caribou Biosciences Inc. [NASDAQ:CRBU] saw its stock fall -0.54% to $5.52. On the same session, the stock had its day’s lowest price of $5.52, but rose to a high of $5.925. Over the last five days, the stock has gained 8.24%. Caribou Biosciences Inc. shares have fallen nearly -63.42% since the year began. SMA at 50 days reached $7.78, while 200 days put it at $14.17. A total of 0.86 million shares were traded, compared to the trading of 0.6 million shares in the previous session.

Levels Of Support And Resistance For CRBU Stock

The 24-hour chart illustrates a support level at 5.38, which if violated will result in even more drops to 5.25. On the upside, there is a resistance level at 5.79. A further resistance level may holdings at 6.06. The Relative Strength Index (RSI) on the 14-day chart is 34.19, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.69, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 85.79%. Stochastics %K at 14.66% indicates the stock is a buying.

Caribou Biosciences Inc. [CRBU] – Who Are The Largest Shareholders?

In filings from PFM Health Sciences LP, it is revealed that the company now owns 4,370,545 shares, or roughly 7.20% of the outstanding CRBU shares. In other words, the investor’s shares have risen by 278,236 from its previous 13-F filing of 4092309.0. Additionally, BlackRock Fund Advisors increased 88.19% of its stake after which the total value it holdings stand at $24,401,044, while Avidity Partners Management LP added 5.42% of its stake to hold $23.48 million in the firm. Over the last quarter, Pictet Asset Management SA purchased 768,117 shares of Caribou Biosciences Inc., while Farallon Capital Management LLC bought -306,396 shares. At present, The Vanguard Group, Inc. is holding 1,922,632 shares valued at $16.02 million. Alkeon Capital Management LLC owned 1,030,670 shares of the company at the time of its most recent 13F filing, worth $8.59 million.

According to FactSet, Caribou Biosciences Inc.’s share price will average $29.43 in the next year, based on opinions of analysts polled by the firm. This is up nearly 404.5 percent from its previous closing price of $5.55. Analysts expect Caribou Biosciences Inc. stock to reach the higher price of $39.00, while the lowest price estimate is $19.00. However, 7 analysts have rated CRBU stock as a Buy in their predictions for 2022. The most recent change occurred on August 17, 2021 when SVB Leerink began covering the stock and recommended ‘”an Outperform”‘ rating along with a $32 price target.

Latest news

Related news


Please enter your comment!
Please enter your name here




Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam